Hematologic Cancer Clinical Trials
To Participate in any of these clinical trials or for more information:
Call us at (808) 586-2979
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Study Number | Study Details |
|---|---|
ECOG-ACRIN-EA9181 Local Principal Investigator: | Official Title: A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Enrollment Status: Open: HCC, Straub, Pali Momi Opt out: QMC Cancer Type: Hematologic Keywords: Newly Dx Subtype: Leukemias ClinicalTrials.gov ID: NCT04530565 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ALLIANCE-A041501 Local Principal Investigator: | Official Title: A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL Enrollment Status: Temporarily Closed to Accrual as of 05/24/2022 Cancer Type: Hematologic Keywords: Precursor B-Cell ALL Subtype: Leukemias ClinicalTrials.gov ID: NCT03150693 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S1918 Local Principal Investigator: | Official Title: A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Patients Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC and BCL2 and/or BCL6 Rearrangements Enrollment Status: Open: HCC, Straub, Pali Momi, QMC Cancer Type: Hematologic Keywords: Lymphoma (DLBCL) Subtype: Lymphomas ClinicalTrials.gov ID: NCT04799275 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
